Game On, page-750

One more thing, with regards to the LOI with that German hospital, it's proposed to commence their in-house trial on Nov 01, 2018 with a six month trial run and a further six month run at no-licence fee to them.  
Reading between the lines, TK must be confident that this DX will have a CE mark well before 1st Nov.  It is also encouraging that the trial (if being successfull) will pave the way for licencing other hospitals and insurance companies, GP clinics etc etc throughout EU/UK and Asia.   
Big year coming up folks!

Brisbane, Australia, 24 April 2018 -- ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has signed a letter of intent (LOI) with a German private hospital network to run a pilot project to test the applicability and integration of ResAppDx, ResApp’s smartphone application for diagnosing acute respiratory disease, within a German hospital structure. The partners will work together to design and run a six-month pilot project at one or more of the network’s hospitals in Germany at no-cost to ResApp. The pilot project must be started by November 1, 2018 and ResApp will not receive revenue from the pilot. At the completion of the project ResApp has agreed to grant the network an exclusive, no-cost license to use ResAppDx in their hospitals in Germany for six months and a non-exclusive, no-cost license for an additional six months. Successful completion of the pilot may lead to the network negotiating a commercial licensing agreement for use in their hospitals. Under the LOI neither party has taken on any obligations regarding ResAppDx following the pilot project and subsequent no-cost license periods. “We are excited to be working with a leading German hospital network. This gives us a unique opportunity to work closely with European clinicians and hospital executives, providing us with invaluable insight into European clinical practice and hospital operations,” said Tony Keating, CEO and Managing Director of ResApp Health. “We expect this project to significantly accelerate the commercialisation of ResAppDx in Europe.”